BiotechTube

IMP321 (eftilagimod alpha) + Placebo + Paclitaxel

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma Breast Stage IV

Conditions

Adenocarcinoma Breast Stage IV

Trial Timeline

Dec 1, 2015 → May 1, 2021

NCT ID
NCT02614833

About IMP321 (eftilagimod alpha) + Placebo + Paclitaxel

IMP321 (eftilagimod alpha) + Placebo + Paclitaxel is a phase 2 stage product being developed by Immutep for Adenocarcinoma Breast Stage IV. The current trial status is completed. This product is registered under clinical trial identifier NCT02614833. Target conditions include Adenocarcinoma Breast Stage IV.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02614833Phase 2Completed

Competing Products

20 competing products in Adenocarcinoma Breast Stage IV

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
44
RamucirumabEli LillyPhase 1/2
41
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
BA3182BioAtlaPhase 1
25
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
33
CT-P16 + AvastinCelltrionPhase 3
77
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
77
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41
EnzalutamideAstellas PharmaPhase 2
52
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23

Other Products from Immutep

eftilagimod alpha + PaclitaxelPhase 2/3
57
Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.vPhase 2
44
Pembrolizumab, Eftilagimod alfaPhase 2
44
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbsPhase 1/2
33
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321Phase 1/2
33